AGARWALEYE - Swing Trade Analysis with AI Signals
Back to List📊 Swing Trade Rating: 3.1
| Stock Code | AGARWALEYE | Market Cap | 14,799 Cr. | Current Price | 467 ₹ | High / Low | 568 ₹ |
| Stock P/E | 344 | Book Value | 62.9 ₹ | Dividend Yield | 0.00 % | ROCE | 5.58 % |
| ROE | 2.19 % | Face Value | 1.00 ₹ | DMA 50 | 454 ₹ | DMA 200 | 455 ₹ |
| Chg in FII Hold | -0.12 % | Chg in DII Hold | 0.05 % | PAT Qtr | 12.6 Cr. | PAT Prev Qtr | 14.6 Cr. |
| RSI | 58.8 | MACD | -2.74 | Volume | 3,14,583 | Avg Vol 1Wk | 1,20,127 |
| Low price | 385 ₹ | High price | 568 ₹ | PEG Ratio | -37.1 | Debt to equity | 0.34 |
| 52w Index | 44.5 % | Qtr Profit Var | -56.7 % | EPS | 1.25 ₹ | Industry PE | 46.3 |
Agarwal Eye Hospital shows weak fundamentals with an extremely high P/E ratio, low ROCE and ROE, negative PEG ratio, and declining profits. Debt-to-equity is moderate, but profitability remains weak. Technically, the stock is trading near its 50 DMA and 200 DMA, with RSI at 58.8 suggesting moderate strength, though MACD is negative, indicating weak momentum. It is a risky candidate for swing trading with limited upside potential.
💡 Optimal Entry Price: Around 455–465 ₹ (near support levels close to DMA 50).
📈 Exit Strategy: If already holding, consider booking profits near 490–500 ₹ (short-term resistance) or exit if price falls below 450 ₹ (support zone).
✅ Positive
- 📈 Large market cap of 14,799 Cr. provides stability.
- 💰 Moderate debt-to-equity ratio of 0.34 keeps leverage manageable.
- 📊 EPS at 1.25 ₹ provides some earnings base.
- 📉 Price trading near DMA 50 and DMA 200, offering technical support.
⚠️ Limitation
- 📉 Extremely high P/E ratio of 344 compared to industry average of 46.3.
- 📉 Weak ROCE at 5.58% and ROE at 2.19% indicate poor efficiency.
- 📉 Negative PEG ratio (-37.1) suggests unsustainable valuation relative to growth.
- 📉 Dividend yield at 0.00% offers no income appeal.
📰 Company Negative News
- 📉 Decline in FII holding (-0.12%) shows reduced foreign investor confidence.
- 📉 PAT dropped from 14.6 Cr. to 12.6 Cr. in the latest quarter.
- 📉 Quarterly profit variation (-56.7%) highlights earnings pressure.
🌟 Company Positive News
- 📈 Increase in DII holding (+0.05%) signals some domestic institutional support.
- 📊 Strong 52-week index performance (+44.5%) shows price momentum despite weak fundamentals.
🏭 Industry
- 📊 Industry P/E at 46.3, far lower than Agarwal Eye’s 344, suggesting sector is moderately valued while the stock is highly overvalued.
- 📈 Healthcare industry remains resilient with long-term demand growth, though margins are under pressure.
📌 Conclusion
Agarwal Eye Hospital presents a weak swing trade opportunity. While market cap and moderate debt are positives, extremely high valuation, poor efficiency metrics, and declining profits limit upside. Entry is favorable near 455–465 ₹, with profit booking advised around 490–500 ₹. Risk management is crucial due to overvaluation and earnings pressure.